Clinical Trial Protocol
Iranian Registry of Clinical Trials

09 Jun 2026

Fasted-state in vivo bioequivalence study of Famotidine 40 mg tablet manufactured by MehrDarou compared with innovator product

Protocol summary

Study aim
In vivo fasted-state bioequivalence study of Famotidine 40 mg tablet

Design
The clinical trial has control and test groups with crossover, randomized design, without blinding. Twenty-four healthy male volunteers will participate randomly in the study as two twelve-person study groups. Each volunteer will receive a single dose of drug in two periods. In one period the test formulation and in another period the reference formulation. Therefore, each volunteer will be his own "Control". To randomly assign participants in two groups, the lottery method will be used.

Settings and conduct
After oral administration of 40 mg tablet to volunteer, the blood samples will be collected in predetermined time intervals up to 12 hours. The samples will be stored in freezer -4 degrees centigrade until analysis and sample quantitation. The concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector. The study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences.

Participants/Inclusion and exclusion criteria
Inclusion criteria: General Health (in terms of Liver, Heart and Kidney); age: 18-59 years old. Exclusion criteria: smoking; history of cardiovascular, liver and kidney disease; pregnancy; alcohol and drug addiction; history of drug allergy.

Intervention groups
Intervention group will receive a single oral dose of test drug product (Famotidine 40 mg tablet manufactured by MehrDarou, Iran) and Control group will receive a single dose of reference drug product (Famotidine 40 mg tablet manufactured by Sandoz). Blood samples will be taken for 12 hours at the mentioned time points after drug administration and the plasma will be stored in freezer until analysis. In both groups, breakfast and lunch will be served two and six hours after drug administration, respectively.

Main outcome variables
Drug plasma concentration

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20210519051345N39**
Registration date: **2023-12-28, 1402/10/07**
Registration timing: **prospective**

Last update: **2023-12-28, 1402/10/07**
Update count: **0**

Registration date
2023-12-28, 1402/10/07

Registrant information

Name
Parvin Zakeri-Milani

Name of organization / entity

Country
Iran (Islamic Republic of)

Phone
+98 41 3334 8801

Email address
pzakeri@tbzmed.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2024-01-10, 1402/10/20

Expected recruitment end date
2024-10-21, 1403/07/30

Actual recruitment start date
empty

Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Fasted-state in vivo bioequivalence study of Famotidine 40 mg tablet manufactured by MehrDarou compared with innovator product

Public title
Bioequivalence study of Famotidine 40 mg tablet
Purpose
Other
Inclusion/Exclusion criteria
Inclusion criteria:
General Health (in terms of Liver, Heart and Kidney) Age (18-59 years)
Exclusion criteria:
Smoking History of cardiovascular disease, liver and kidney disease Pregnancy Alcohol and drug addiction History of drug allergy
Age
From **18 years** old to **59 years** old
Gender
Both

Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: **24**
Randomization (investigator's opinion)
Randomized
Randomization description
To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Biomedical Research Committe, Tabriz University of Medical Sciences
Street address
No.2 Central Building 3rd Floor, Tabriz University of Medical Sciences, Daneshgah st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Approval date
2023-12-18, 1402/09/27
Ethics committee reference number
IR.TBZMED.REC.1402.688

Health conditions studied

1

Description of health condition studied
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Plasma concentration of drug
Timepoint
0.5-12 hours in predetermined time intervals after drug administration
Method of measurement
HPLC (High performance liquid chromatography)

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Intervention group will receive a single oral dose of test product (Famotidine 40 mg tablet manufactured by MehrDarou, Iran) in fasted state. Blood samples will be collected for 12 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively
Category
Treatment - Drugs

2

Description
Control group: Control group will receive a single oral dose of reference product (Famotidine 40mg tablet manufactured by Sandoz) in fasted state. Blood samples

will be collected for 12 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively.

Category
Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center
Faculty of Pharmacy, Tabriz University of Medical Sciences

Full name of responsible person
Parvin Zakeri-Milani

Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.

City
Tabriz

Province
East Azarbaijan

Postal code
51664-14766

Phone
+98 41 3334 8801

Email
pzakeri@tbzmed.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Parviz Shahabi

Street address
No.2 Central Building 3rd Floor, Tabriz University of Medical Science, Daneshgah st.

City
Tabriz

Province
East Azarbaijan

Postal code
51664-14766

Phone
+98 41 3334 8801

Email
shahabip@tbzmed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?
No

Title of funding source
MehrDarou Pharmaceutical company

Proportion provided by this source
100

Public or private sector
Private

Domestic or foreign origin
Domestic

Category of foreign source of funding
empty

Country of origin

Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Parvin Zakeri-Milani

Position
Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.

City
Tabriz

Province
East Azarbaijan

Postal code
51664-14766

Phone
+98 41 3334 8801

Email
pzakeri@tbzmed.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Parvin Zakeri-Milani

Position
Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.

City
Tabriz

Province
East Azarbaijan

Postal code
51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences; Attar Neishaboori st., Golgasht st.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable